NASDAQ:CRTX - Chiesi USA Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
Previous CloseN/A
Today's RangeN/A
52-Week RangeN/A
VolumeN/A
Average VolumeN/A
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Cornerstone Therapeutics Inc. is a specialty pharmaceutical company focused on commercializing products for the hospital, respiratory and related specialty markets. The Company's promoted products include CUROSURF, ZYFLO CR, FACTIVE and SPECTRACEF. On December 30, 2011, the Company acquired Cardiokine, Inc., a specialty pharmaceutical company, focused on developing hospital products for cardiovascular indications. In March 2012, it acquired the North American product rights for FACTIVE (Gemifloxacin Mesylate) tablets. In June 2012, the Company acquired EKR Therapeutics, Inc. In February 2014, Chiesi Farmaceutici S.p.A acquired Cornerstone Therapeutics Inc.

Receive CRTX News and Ratings via Email

Sign-up to receive the latest news and ratings for CRTX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry N/A
Sub-IndustryPharmaceuticals
SectorN/A
SymbolNASDAQ:CRTX
CUSIP21924P10
Phone+1-919-6786611

Debt

Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A

Profitability

EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A

Miscellaneous

EmployeesN/A
Outstanding SharesN/A

The Truth About Cryptocurrencies

Chiesi USA (NASDAQ:CRTX) Frequently Asked Questions

What is Chiesi USA's stock symbol?

Chiesi USA trades on the NASDAQ under the ticker symbol "CRTX."

Who are Chiesi USA's key executives?

Chiesi USA's management team includes the folowing people:
  • Kenneth R. McBean, President (Age 48)
  • Craig Alexander Collard, Chief Executive Officer
  • Alastair S. McEwan, Chief Financial Officer, Treasurer, Secretary (Age 62)
  • Andreas Maetzel, Vice President - Clinical and Regulatory (Age 50)
  • Alan T. Roberts, Vice President - Scientific Affairs (Age 47)
  • Joshua B. Franklin, Vice President - Strategy and Business Development (Age 44)
  • Ugo Di Francesco, Director

Has Chiesi USA been receiving favorable news coverage?

Headlines about CRTX stock have trended somewhat negative recently, Accern Sentiment reports. The research group scores the sentiment of news coverage by reviewing more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Chiesi USA earned a daily sentiment score of -0.06 on Accern's scale. They also assigned press coverage about the specialty pharmaceutical company an impact score of 46.52 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company's share price in the immediate future.

How do I buy shares of Chiesi USA?

Shares of CRTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How can I contact Chiesi USA?

Chiesi USA's mailing address is 1255 Crescent Grn Ste 250, CARY, NC 27518-8128, United States. The specialty pharmaceutical company can be reached via phone at +1-919-6786611.


MarketBeat Community Rating for Chiesi USA (CRTX)

Community Ranking:  2.3 out of 5 (star star)
Outperform Votes:  50 (Vote Outperform)
Underperform Votes:  61 (Vote Underperform)
Total Votes:  111
MarketBeat's community ratings are surveys of what our community members think about Chiesi USA and other stocks. Vote "Outperform" if you believe CRTX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CRTX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 6/24/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.